{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 456688736
| IUPAC_name = 1,3-Dimethyl-7''H''-purine-2,6-dione; ethane-1,2-diamine
| image = Aminophylline.svg
| width = 250

<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|CDI|aminophylline}}
| MedlinePlus = a601015
| pregnancy_AU = A
| pregnancy_US = C
| pregnancy_category =
| legal_AU = S3
| legal_CA =
| legal_UK = P
| legal_US =
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]], [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 60%
| metabolism =
| elimination_half-life = 7–9 hours

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 317-34-0
| ATC_prefix = R03
| ATC_suffix = DA05
| ATC_supplemental =
| PubChem = 9433
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01223
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9062
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 27Y3KJK423
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00227
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1210

<!--Chemical data-->
| C=16 | H=24 | N=10 | O=4
| molecular_weight = 420.427 g/mol
| smiles = O=C2N(c1ncnc1C(=O)N2C)C.O=C2N(c1ncnc1C(=O)N2C)C.NCCN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FQPFAHBPWDRTLU-UHFFFAOYSA-N
}}

'''Aminophylline''' is a compound of the [[bronchodilator]] [[theophylline]] with [[ethylenediamine]] in 2:1 ratio. The ethylenediamine improves solubility, and the aminophylline is usually found as a [[hydrate|dihydrate]].<ref>{{cite web |title= Aminophylline Professional Monograph |url= http://www.drugs.com/pro/aminophylline-injection.html |work=Drugs.com}}</ref>

Aminophylline is less potent and shorter-acting than [[theophylline]]. Its most common use is in the treatment of airway obstruction from asthma or COPD.  It is used off-label as a reversal agent during nuclear stress testing.  Aminophylline is a nonselective adenosine receptor antagonist and phosphodiesterase inhibitor.<ref name="Mader 2003 192–197">{{cite journal|author1=Mader TJ|author2=Smithline HA |author3=Durkin L |author4=Scriver G |title=A randomized control trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest|journal=Academic Emergency Medicine|date=March 2003|volume=10|issue=3|pages=192–197 |doi=10.1197/aemj.10.3.192 |pmid=12615581}}</ref>

==Medical uses==
Aminophylline is used to reverse [[regadenoson]], [[dipyridamole]] or adenosine based infusions during nuclear cardiology stress testing.

Aminophylline has shown some promise as a bodyfat reducer when used as a topical cream.<ref name="pmid17391155">{{cite journal |vauthors=Caruso MK, Pekarovic S, Raum WJ, Greenway F |title=Topical fat reduction from the waist |journal=Diabetes, Obesity & Metabolism |volume=9 |issue=3 |pages=300–3 |date=May 2007 |pmid=17391155 |doi=10.1111/j.1463-1326.2006.00600.x}}</ref> Aminophylline is also a treatment option for [[anaphylactic shock]].<ref>Blackbourne LH. Surgical Recall. Lippincott Williams and Wilkins, 2009. pp169</ref>

While it has been suggested for use in [[cardiac arrest]] evidence does not support a benefit.<ref name="PMID17652689">{{citation |pmid=17652689 |title=Aminophylline in bradyasystolic cardiac arrest |journal=Emerg. Med. J. |year=2007 |volume=24 |issue=8 |pages=582–3 |pmc=2660094 |doi=10.1136/emj.2007.051342|author1=Hayward E |author2=Showler L |author3=Soar J}}</ref><ref>{{cite journal|last1=Hurley|first1=KF|last2=Magee|first2=K|last3=Green|first3=R|title=Aminophylline for bradyasystolic cardiac arrest in adults|journal=The Cochrane database of systematic reviews|date=23 November 2015|volume=11|issue=11|pages=CD006781|pmid=26593309|doi=10.1002/14651858.CD006781.pub3}}</ref>

The tablets are no longer sold but the injection is still sold as of 2017

==Side effects==
Aminophylline can lead to theophylline toxicity. Aminophylline has been found to decrease the sedative effects of [[propofol]]<ref>{{cite journal|author1=Turan A|author2=Kasuya Y |author3=Govinda R |author4=Obal D |author5=Rauch S |author6=Dalton J |title=The effect of aminophylline on loss of consciousness, bispectral index, propofol requirement, and minimum alveolar concentration of desflurane in volunteers|journal=Anesthesia and Analgesia|date=February 2010|volume=110|issue=2|pages=449–454|url=http://www.anesthesia-analgesia.org/content/110/2/449|accessdate=Feb 17, 2012|doi=10.1213/ane.0b013e3181c6be7e|pmid=19955506|display-authors=etal}}</ref>  and decrease [[topiramate]] antiseizure action.<ref>{{cite journal|author1=Luszczki JJ |author2=Jankiewicz K |author3=Jankiewicz M |author4=Czuczwar SJ |title=Pharmacokinetic and pharmacodynamic interactions of aminophylline and topiramate in the mouse maximal electroshock-induced seizure model|journal=European Journal of Pharmacology|date=May 2007|volume=562|issue=1–2|pages=53–59 |doi=10.1016/j.ejphar.2007.01.038|pmid=17320861}}</ref>

==Properties==
It is more [[soluble]] in water than theophylline. White or slightly yellowish granules or powder, having a slight ammoniacal odor and a bitter taste. Upon exposure to air, it gradually loses ethylenediamine and absorbs [[carbon dioxide]] with the liberation of free theophylline. Its solutions are [[alkaline]]. 1 g dissolves in 25 mL of water to give a clear solution; 1 g dissolved in 5 mL of water crystallizes upon standing, but redissolves when a small amount of ethylenediamine is added. Insoluble in alcohol and in ether.

==Mechanism of action==
Like other methylated [[xanthine|xanthine derivatives]], aminophylline is both a
# competitive nonselective [[phosphodiesterase inhibitor]]<ref name="PDEs-Essayan">{{cite journal | author=Essayan DM. | title=Cyclic nucleotide phosphodiesterases. | journal=J. Allergy. Clin. Immunol. | year=2001 | pages=671–80 | volume=108 | issue=5 | pmid=11692087 | doi=10.1067/mai.2001.119555 }}</ref> which raises intracellular [[Cyclic adenosine monophosphate|cAMP]], activates [[cAMP-dependent protein kinase|PKA]], [[TNF inhibitor|inhibits TNF-alpha]]<ref name="PTX-Deree">{{cite journal |vauthors=Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R | title=Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition | journal=Clinics | year=2008 | pages=321–8 | volume=63 | issue=3 | pmid=18568240 | doi=10.1590/S1807-59322008000300006 | pmc=2664230 }}</ref><ref name="pmid9927365">{{cite journal |vauthors=Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U |title=Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages |journal=Am. J. Respir. Crit. Care Med. |volume=159 |issue=2 |pages=508–11 |date=February 1999 |pmid=9927365 |doi= 10.1164/ajrccm.159.2.9804085 }}</ref> and [[leukotriene]]<ref name="LT-Peters-Golden">{{cite journal |vauthors=Peters-Golden M, Canetti C, Mancuso P, Coffey MJ | title=Leukotrienes: underappreciated mediators of innate immune responses | journal=J. Immunol. | year=2005 | pages=589–94 | volume=174 | issue=2 | pmid=15634873 | url=http://www.jimmunol.org/cgi/content/full/174/2/589 | doi=10.4049/jimmunol.174.2.589}}</ref> synthesis, and [[Anti-inflammatory|reduces inflammation]] and [[innate immunity]]<ref name="LT-Peters-Golden"/> and
# nonselective [[adenosine receptor]] antagonist.<ref name="AR-Daly">{{cite journal |vauthors=Daly JW, Jacobson KA, Ukena D | title=Adenosine receptors: development of selective agonists and antagonists | journal=Prog. Clin. Biol. Res. | year=1987 | pages=41–632 | volume=230 | issue=1 | pmid=3588607 }}</ref>

Aminophylline causes bronchodilation, diuresis<sup>†</sup>, [[central nervous system]] and cardiac stimulation, and gastric acid secretion by blocking phosphodiesterase which increases tissue concentrations of [[cyclic adenosine monophosphate]] (cAMP) which in turn promotes [[catecholamine]] stimulation of [[lipolysis]], [[glycogenolysis]], and [[gluconeogenesis]], and induces release of [[epinephrine]] from adrenal medulla cells.<br />
<sup>†</sup>Note that diuresis is caused by an increase in cAMP which acts in the CNS to inhibit the release of [[Vasopressin|antidiuretic hormone]] (arginine-vasopressin).

Adenosine is an endogenous extracellular messenger that can regulate myocardial oxygen needs.<ref name="Mader 2003 192–197"/><ref name="Mader 1997 3–7">{{cite journal|last=Mader|first=TJ|author2=Gibson, P|title=Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study|journal=Resuscitation|volume=35|issue=1|pages=3–7 |date=7 January 1997|doi=10.1016/s0300-9572(97)01097-6|pmid=9259053}}</ref> It acts through cellular surface receptors which effect intracellular signalling pathways to increase coronary artery blood flow, slow heart rate, block atrioventricular node conduction, suppress cardiac automaticity, and decrease β-adrenergic effects on contractility.<ref name="Mader 2003 192–197"/><ref name="Mader 1997 3–7"/> Adenosine also antagonizes chronotropic and ionotropic effects of circulating catecholamines.<ref name="Perouansky 1998 39–41">{{cite journal|last=Perouansky|first=M|author2=Shamir M |author3=Hershkowitz E |author4=Donchin Y |title=Successful resuscitation using aminophylline in refrectory cardiac arrest with asystole|journal=Resuscitation|volume=38|issue=1|pages=39–41 |date=12 June 1998|doi=10.1016/s0300-9572(98)00079-3|pmid=9783508}}</ref> Overall, adenosine decreases the heart’s rate and force of contraction, which increases blood supply to the cardiac muscle. Given specific circumstances this mechanism (which is intended to protect the heart) may cause atropine-resistant refractory bradyasystole.<ref name="Mader 2003 192–197"/> Adenosine's effects are concentration-dependent. Adenosine’s receptors are competitively antagonized by methylxanthines such as aminophylline.<ref name="Mader 2003 192–197"/><ref name="Mader 1997 3–7"/><ref name="Perouansky 1998 39–41"/> Aminophylline competitively antagonizes the cardiac actions of adenosine at the cell surface receptors.<ref name="Mader 1997 3–7"/> Thus, it increases heart rate and contractility.

==Brand names==
* Euphyllin
* Phyllocontin
* Truphylline
* Minomal R 175&nbsp;mg tab
* Minomal R 350&nbsp;mg tab
* Minomal SR 600&nbsp;mg tab

==References==
{{reflist|2}}

{{Asthma and copd rx}}
{{Adenosinergics}}
{{Phosphodiesterase inhibitors}}

[[Category:Adenosine receptor antagonists]]
[[Category:Bronchodilators]]
[[Category:Phosphodiesterase inhibitors]]
[[Category:Xanthines]]